Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 17/20 | 1.00 |
| ▸ | HTR2C | P28335 | 2/20 | 1.00 |
| ▸ | HTR7 | P34969 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | CYP2A6 | P11509 | 1/20 | 1.00 |
| ▸ | HTR2B | P41595 | 1/20 | 1.00 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.93 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.93 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.93 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.93 |
| ▸ | C5AR1 | P21730 | 1/20 | 0.93 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.93 |
| ▸ | FPR3 | P25089 | 1/20 | 0.93 |
| ▸ | HTR1D | P28221 | 1/20 | 0.93 |
| ▸ | HTR1B | P28222 | 1/20 | 0.93 |
| ▸ | HTR2A | P28223 | 1/20 | 0.93 |
| ▸ | GPR183 | P32249 | 1/20 | 0.93 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.93 |
| ▸ | HRH1 | P35367 | 1/20 | 0.93 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL4018430 | 0.99 | HTR6 (0.98) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL5738583 | 0.94 | HTR6 (0.89) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL5739275 | 0.90 | HTR6 (0.82) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL5738489 | 0.88 | HTR6 (0.79) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL5738365 | 0.87 | HTR6 (0.78) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL3893125 | 0.87 | HTR6 (0.78) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL3889054 | 0.87 | HTR6 (0.78) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL5738575 | 0.87 | HTR6 (0.78) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL5739503 | 0.87 | HTR6 (0.76) | HTR6HTR2CHTR7CYP3A4CYP2A6 | |
| SCHEMBL5738640 | 0.87 | HTR6 (0.76) | HTR6HTR2CHTR7CYP3A4CYP2A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | claimed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | claimed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | claimed |
| EP-1455779-B1 | INDOLYLALKYLAMINE DERIVATIVES AS 5-HYDROXYTRYPTAMINE-6 LIGANDS | WYETH CORP (US) | 2006-08-09 | — | — | EP | claimed |
| US-7022701-B2 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-04-04 | — | — | US | claimed |
| US-20040209867-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-10-21 | — | — | US | claimed |
| US-6770642-B2 | FOR USE IN TREATMENT OF CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, EPILEPSY, OBSESSIVE COMPULSIVE DISORDER, ATTENTION DEFICIT DISORDER, MIGRAINE, COGNITIVE MEMORY ENHANCEMENT, ALZHEIMER'S DISEASE | WYETH | 2004-08-03 | — | — | US | claimed |
| US-20030171353-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | claimed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | THE SCRIPPS RESEARCH INSTITUTE | 2023-11-02 | — | — | US | disclosed |
| US-20230035892-A1 | METHODS AND COMPOSITIONS FOR TREATING CANCER | FLAGSHIP PIONEERING, INC. | 2023-02-02 | — | — | US | disclosed |
| US-20220146492-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | SHINE IAN BASIL (US) | 2022-05-12 | — | — | US | disclosed |
| US-11274158-B2 | Methods and compositions for treating inflammatory or autoimmune diseases or conditions using calcitonin receptor activators | FLAGSHIP PIONEERING INNOVATIONS V, INC. (US) | 2022-03-15 | — | — | US | disclosed |
| EP-3953000-A1 | CELL MEMBRANE PERMEABILITY RESTORING THERAPY | Shine, Ian Basil (US) | 2022-02-16 | — | — | EP | disclosed |
| US-7022701-B2 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-04-04 | — | — | US | disclosed |
| US-20060003945-A1 | Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands | WYETH (US) | 2006-01-05 | — | — | US | disclosed |
| WO-2006002125-A1 | INDOLYLALKYLAMINE METABOLITES AS 5-HYDROXYTRYTAMINE-6 LIGANDS | WYETH (US) | 2006-01-05 | — | — | WO | disclosed |
| US-20040209867-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2004-10-21 | — | — | US | disclosed |
| US-6770642-B2 | FOR USE IN TREATMENT OF CNS DISORDERS SUCH AS ANXIETY, DEPRESSION, EPILEPSY, OBSESSIVE COMPULSIVE DISORDER, ATTENTION DEFICIT DISORDER, MIGRAINE, COGNITIVE MEMORY ENHANCEMENT, ALZHEIMER'S DISEASE | WYETH | 2004-08-03 | — | — | US | disclosed |
| US-20030171353-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | WYETH | 2003-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060003945-A1 | Indolylalkylamine metabolites as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, TPH1 | HTR6 1/4885HTR2C 11/4885HTR7 9/4885 |
| US-20230346820-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF SARS-COV-2 | ACE2, SARS1, ACE | HTR6 1569/4885HTR2C 1982/4885HTR7 2058/4885 |
| US-20040209867-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885HTR2C 8/4885HTR7 7/4885 |
| US-20030171353-A1 | Indolylalkylamine derivatives as 5-hydroxytryptamine-6 ligands | HTR6, HTR5A, HTR1A | HTR6 1/4885HTR2C 8/4885HTR7 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.